Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of GC4419 in Renal Impairment
NCT05412472Phase 1Completed
- Sponsor
- Galera Therapeutics, Inc.
- Start
- Apr 2019
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of avasopasem manganese in oral mucositis (OM) (4 arms), sponsored by Galera Therapeutics, Inc. Primary endpoints: Area Under the Curve from time 0 to the last measurable concentration at 36 hours, Area Under the Curve from time 0 to infinity at 36 hours and 7 more. Started Apr 2019; status: completed.
02
Drugs
avasopasem manganese
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT05412472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05412472.